Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of human coronary artery endothelial cells treated with ADMA at 2uM (a pathophysiological dose) and 100uM (a pharmacological dose), for 24h
Asymmetric dimethylarginine (ADMA) is a naturally occurring inhibitor of nitric oxide synthesis that accumulates in wide range of diseases associated with endothelial dysfunction and enhanced atherosclerosis. Plasma ADMA has been implicated as a major novel cardiovascular risk factor, but the mechan...
ORGANISM(S): Homo sapiens 
2005-09-01 | E-MEXP-377 | biostudies-arrayexpress
UnknownRegional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis.
Not available
S-EPMC10878545 | biostudies-literature
UnknownBeyond mild, moderate, and severe traumatic brain injury: modelling severity from clinical, neuroimaging, and blood-based indicators.
Not available
S-EPMC12637077 | biostudies-literature
UnknownCost-Utility Analysis of Accelerated and Standard Strategies for Renal Replacement Therapy Initiation.
Not available
S-EPMC12495491 | biostudies-literature
UnknownFactors associated with adverse haemodynamic events during the STARRT-AKI trial: a post-hoc secondary analysis.
Not available
S-EPMC12751851 | biostudies-literature
UnknownA Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
Not available
S-EPMC9404618 | biostudies-literature
Sort   by:  
 Page size